More specifically, for head and neck squamous cell carcinoma, the PD-1 inhibitor pembrolizumab is approved as a single agent for patients whose tumors express PD-L1, and nivolumab and pembrolizumab are also approved for second-line treatment of recurrent and metastatic tumors [19]. This evidence concerns the gene CD274 and metastatic neoplasm.